ImmunoCellular Therapeutics (IMUC) 10-Q2016 Q3 Quarterly report

Filed: 10 Nov 16, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: abnormally, accelerate, accelerated, accurately, adequacy, AG, aggressively, Amgen, antibody, apherese, ascribed, attempted, auction, Bavarian, began, biological, Biomed, Biopharma, biopharmaceutical, BMS, bring, broad, Celgene, characterized, checkpoint, chemical, collect, competition, competitive, complex, contamination, costly, CRO, DCPrime, DCs, DCVax, demonstrate, desired, device, devote, difficulty, disadvantage, discount, discovered, disease, disrupt, distributor, diversity, Domestic, donor, efficacy, electric, eligibility, encounter, essential, expended, experienced, expertise, factor, field, foreign, formulated, formulating, frequency, Galena, GBM, Genentech, GlaxoSmithKline, Guide, harmful, harvested, healthcare, healthy, heat, human, Immunovaccine, individual, industry, ineffective, Infinity, infrastructure, inhibitor, intense, intensify, interact, intermediate, ipilimumab, Juno, Kite, knowledge, laboratory, large, lot, lysate, manner, mentioned, Merck, methylated, MGMT, microbial, monitor, mycoplasma, negative, negatively, network, nivolumab, Nordic, North, Northwest, Novocure, obsolete, OncoMed, Oncothyreon, Optune, outsource, outsourced, oversight, past, payor, peptide, Pharma, pharmacological, placebo, plc, population, preclinical, presence, prevalence, Prima, produce, producing, promoting, proportional, protein, protocol, prove, proximity, publicly, pursuing, question, rapid, rapidly, recover, reliably, remedy, responsibility, retain, reverse, Roche, run, safety, scale, screening, select, shock, side, size, source, speed, spend, split, Squibb, stability, stage, Stemline, strategy, study, submission, successfully, suitable, superior, target, team, therapeutic, tumor, typical, unable, unforeseen, unmethylated, validation, Verastem, verify, viable, viral

Removed: abated, anticipate

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

IMUC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER

Pursuant to the requirement set forth in Rule 13a -14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. § 1350), the undersigned officer of ImmunoCellular Therapeutics, Ltd. (the “Company”) hereby certifies that, to the best of his knowledge:


1.	The Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2016 (“Periodic Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and


2.	The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date: November 10, 2016	By:	/s/ Andrew Gengos
		Name:	Andrew Gengos
		Title:	President and Chief Executive Officer